Lenalidomid Zentiva

Lenalidomide, the active ingredient in Lenalidomid Zentiva, is an immunomodulatory agent presented as an oral tablet for systemic use. It is employed in the treatment of certain blood cancers, notably multiple myeloma and myelodysplastic syndromes, in adult patients and are prescribed by qualified oncologists.

GNH USA supplies Lenalidomid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across global markets.

Lenalidomide is used in hematologic malignancies, targeting abnormal plasma cells and dysplastic bone marrow. - Multiple myeloma: improves progression‑free survival and overall response rates in relapsed or refractory disease. - Myelodysplastic syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. - Multiple myeloma (maintenance after autologous stem cell transplant): prolongs disease‑free interval and supports long‑term control.

Lenalidomid Zentiva may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Fatigue: persistent tiredness affecting daily activities. - Neutropenia: reduced neutrophil count increasing infection risk. - Diarrhea: loose stools that may lead to dehydration. - Rash: mild skin eruptions or itching.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers unrelated to original disease. - Severe hepatic injury: marked elevation of liver enzymes or liver failure.

When prescribing Lenalidomid Zentiva, clinicians should observe several precautionary measures to minimize risks. - Pregnancy contraindication: drug is teratogenic (Category X) and must not be used during pregnancy. - Thrombosis risk: assess patient history and consider prophylactic anticoagulation. - Hematologic monitoring: perform regular complete blood counts to detect neutropenia or thrombocytopenia. - Renal impairment: adjust dose in patients with reduced kidney function. - Drug interaction awareness: avoid concomitant use with thalidomide or strong CYP3A4 inhibitors. - Store at ambient temperature below 25°C: keep in the original packaging, protect from moisture and light.

Lenalidomid Zentiva can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Thalidomide: combined use increases risk of severe teratogenicity and neuropathy. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise lenalidomide plasma levels. - Anticoagulants (warfarin, direct oral anticoagulants): heightened risk of bleeding events.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure. - NSAIDs: can exacerbate renal toxicity when used together. - Live vaccines: immunosuppression may diminish vaccine efficacy.